BrainsWay posts Q3 2026 revenue growth, highlights clinical data and new clinic partnership
BrainsWay reported third-quarter 2026 revenue of $18.1 million, cited new suicidal ideation and Alzheimer's-related data, and disclosed a post-quarter collaboration with a Southern California psychiatric network.
BrainsWay Ltd. reported third quarter 2026 results on November 10, 2026, showing revenue of $18.1 million, up 34% from $13.5 million in the third quarter of 2025.1 The company said it shipped 130 Deep TMS systems in the quarter, a 44% increase over the same period last year, bringing the total installed base to approximately 2,080 systems.1 Sales of the OCD coil also grew, with OCD coil sales up 17% year-over-year to 54 coils, lifting the installed OCD coil base to roughly 1,000 units.1
On the clinical side, BrainsWay pointed to peer-reviewed data showing a 70% relative reduction in patients experiencing suicidal ideation after six weeks of Deep TMS treatment, using both the SWIFT accelerated protocol and the standard once-daily protocol.1 The company also reported pilot findings in a separate population, stating that the data showed an 83.3% response rate and a 50% remission rate in depressive symptoms among patients with depression and comorbid early-stage Alzheimer's disease, which it said support further clinical research.1 The release noted that Deep TMS is not FDA cleared for the treatment of suicidal ideation or for comorbid early-stage Alzheimer's disease.1
On reimbursement, BrainsWay said payer policy data it compiled show favorable coverage for the SWIFT accelerated protocol now extends to more than 70 million covered lives in the U.S.1
Subsequent to the quarter, BrainsWay said it entered a strategic collaboration with Inland Psychiatric Medical Group, described as a clinical network in Southern California with more than 30 locations, that includes a multisystem Deep TMS order for installation at its clinics along with plans to explore joint scientific, clinical and research projects.1
On cash, the company reported cash and cash equivalents, short-term deposits and restricted cash of $63.4 million as of September 30, 2026, up about 1% from June 30, 2026, and operating cash flow of $6.2 million for the quarter.1 BrainsWay said it now expects full-year 2026 results to come in at the upper end of its previously issued guidance ranges, with potential to modestly exceed that guidance.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.